Levicept presents new LEVI-04 data at EULAR
Biotech firm shares phase 2 findings on novel osteoarthritis treatmen Levicept has presented new data from its phase 2 trial...
Selected News
Migraine takes the spotlight at European Parliament
EMHA calls for its inclusion in EU neurological health strategy The European Migraine and Headache Alliance (EMHA) has urged EU...
Bimekizumab shows lasting efficacy at EULAR 2025
Three-year data highlights inflammation control in psoriatic arthritis UCB has announced new three-year data from phase 3 trials and their...
Argenx presents new efgartigimod data at EULAR 2025
Rheumatology studies show promising results for Sjogren’s disease Argenx has presented positive phase 2 results for efgartigimod in myositis and...
Tagomics secures £860k grant for colorectal cancer test
Biotech firm to collaborate with NHS on early detection study Tagomics has been awarded £860k in funding from Innovate UK’s...
EC approves Santen’s Ryjunea to slow progression of paediatric myopia
Therapy indicated for children aged 3 to 14 at treatment initiation Santen has announced that the European Commission has granted...
Linear Diagnostics awarded £1m to develop rapid STI test
New funding supports development of diagnostic platform Birmingham spin-out Linear Diagnostics has secured £1m funding to advance a rapid test...
NICE recommends Sogroya for growth hormone deficiency in children
Treatment provides option for children with growth failure The National Institute for Health and Care Excellence (NICE) has recommended Sogroya...
PharmaTimes Clinical Researcher of the Year – The Americas
Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas! Enter The 2025 PharmaTimes Clinical Researcher of the...
NICE recommends mirikizumab for Crohn’s disease treatment
New guidance expands treatment options for eligible patients The National Institute for Health and Care Excellence (NICE) has issued final...
AstraZeneca’s Forxiga recommended for chronic kidney disease treatment
Updated guidance from NICE expands eligibility for dapagliflozin us The National Institute for Health and Care Excellence (NICE) has published...
Lumanity and Parker Institute partner to support delivery of new immunotherapies
The alliance combines Lumanity’s commercial and development strategy capabilities with PICI’s translational research expertise Lumanity and the Parker Institute for...
TQ Therapeutics acquires Juno GmbH to support decentralised cell therapy platform
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, through a share purchase agreement. Juno...
Eli Lilly acquires SiteOne Therapeutics to advance treatment for chronic pain
Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid medicines to treat pain...
MHRA Board meets in Scotland for first time, reinforcing UK-wide health priorities
The Board of the Medicines and Healthcare products Regulatory Agency (MHRA) has met in Scotland for the first time, marking...
MHRA Board meets in Scotland for first time, reinforcing UK-wide health priorities
The Board of the Medicines and Healthcare products Regulatory Agency (MHRA) has met in Scotland for the first time, marking...
Sonrai and AOA Dx partner to accelerate ovarian cancer test development
Strategic collaboration aims to improve early diagnosis Sonrai Analytics and AOA Dx have announced a partnership to accelerate the development...
Ionis shares phase 3 results for olezarsen in moderate hypertriglyceridaemia
The drug was recently approved in the US for familial chylomicronaemia syndrome Ionis Pharmaceuticals has shared positive top-line results from...
FDA approves Amneal’s self-administered migraine drug Brekiya
Brekiya is now the first DHE auto-injector to be approved by the regulator The US Food and Drug Administration (FDA)...
MHRA approves guselkumab for Crohn’s disease and ulcerative colitis
Regulator confirms safety and efficacy of new treatment option for patient The Medicines and Healthcare products Regulatory Agency (MHRA) has...
